fibromyalgia and glp 1 A large review of almost 100,000 individuals with fibromyalgia, comparing those who were were not taking GLP‑1 receptor‑agonists (the same drugs that help with diabetes and weight loss). After matching the NEW RESEARCH! GLP-1 receptor agonists

Wondering whether GLP-1 is a lifelong commitment

N = 161,798 after matching GLP-1RA vs diet/exercise consultation Median follow-up: 2 years Key result: Any obesity-associated cancer HR 0.59, 95% CI 0.53-0.67 Site-specific signals: Multiple myeloma HR 0.37 Pancreatic cancer HR 0.40 Endometrial cancer HR 0.42 Colorectal cancer HR 0.49 But remember: This is observational

Results The study consisted of 150 patients, with 73 GLP-1 RA users in the experimental group and 77 non-users in the control group

Midi Health operates as a telemedicine platform offering GLP-1 medications with subscription-based pricing

People on GLP-1s had slightly higher risks of osteoporosis and gout than similar people not taking these drugs

GLP-1 drugs such as semaglutide are reshaping treatment of obesity, diabetes and cardiovascular disease with broader physiological effects now emerging.